Agenus Inc.
AGEN · United States
Share price · AGEN
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when AGEN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 6 Nov 2026+11.0%
- 13 Jul 2026+82.7%
- 1 Jul 2026+11.4%
Nothing announced by AGEN that day or the session before.
- 11 May 2026-14.7%
- 21 Apr 2026-11.5%
- 14 Apr 2026+13.7%
Nothing announced by AGEN that day or the session before.
- 6 Apr 2026+13.2%
- 17 Mar 2026+21.3%
- 16 Jan 2026-9.2%
- 15 Jan 2026-21.4%
Share of unusual movement by asset
For each asset, the share of AGEN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | CTLA-4Monoclonal antibody | Non-Small Cell Lung CancerColorectal Cancer | |
| Phase 2 | PD-1Monoclonal antibody | Non-Small Cell Lung CancerCervical Cancer |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
September 2027 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $31M | $12M | $67M+ $20M short-term inv. | —-$20M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $35M | $15M | $19M | —-$31M operating cash flow | report ↗ |
| 2026-Q1 | $34M | $12M | $35M | —-$36M operating cash flow | report ↗ |
| 2025-Q3 | $30M | $24M | $3.5M+ <$0.1M short-term inv. | —-$15M operating cash flow | report ↗ |
| 2025-Q2 | $26M | $27M | $9.5M | —-$20M operating cash flow | report ↗ |
| 2025-Q1 | $24M | $22M | $18M+ <$0.1M short-term inv. | —-$26M operating cash flow | report ↗ |
| 2024-Q3 | $25M | $41M | $45M+ <$0.1M short-term inv. | —-$53M operating cash flow | report ↗ |
| 2024-Q2 | $24M | $37M | $94M | —-$38M operating cash flow | report ↗ |
| 2024-Q1 | $28M | $44M | $53M+ <$0.1M short-term inv. | —-$38M operating cash flow | report ↗ |
| 2023-Q3 | $24M | $51M | $106M | —-$65M operating cash flow | report ↗ |
| 2023-Q2 | $25M | $59M | $143M+ $15M short-term inv. | —-$60M operating cash flow | report ↗ |
| 2023-Q1 | $23M | $57M | $165M+ $24M short-term inv. | —-$59M operating cash flow | report ↗ |
| 2022-Q3 | $23M | $46M | $208M+ $9.9M short-term inv. | —-$32M operating cash flow | report ↗ |
| 2022-Q2 | $21M | $45M | $228M+ $9.9M short-term inv. | —-$43M operating cash flow | report ↗ |
| 2022-Q1 | $26M | $42M | $248M+ $15M short-term inv. | —-$52M operating cash flow | report ↗ |
| 2021-Q3 | $253M | $43M | $257M+ $5.0M short-term inv. | —$131M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $114M | $79M | $3.0M+ $0 short-term inv. | $0.8M-$77M operating cash flow | report ↗ |
Agenus reported full-year 2025 revenue of $114.2M, up 10.4% YoY, with R&D spend of $79.34M, down 49.0% YoY. The company ended the period with $3M in cash and equivalents and reported a net loss of $3.08M, reflecting a quarterly net burn of $3.08M.
Business highlights centered on the BOT+BAL immunotherapy program: the Phase 3 BATTMAN registrational trial in refractory MSS metastatic colorectal cancer was initiated, and global early access programs expanded, generating initial program revenue of $4.2M from 200+ physician inquiries across 30+ countries. The Zydus collaboration closed with $91M in upfront capital, plus a $20M contingent payment triggered in March 2026, and clinical data included a 42% two-year overall survival and ~21-month median overall survival in heavily pretreated MSS mCRC patients.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $103M | $156M | $40M | $58M-$158M operating cash flow | report ↗ |
| 2023-FY | $156M | $235M | $76M | $64M-$224M operating cash flow | report ↗ |
| 2022-FY | $98M | $187M | $179M+ $15M short-term inv. | —-$175M operating cash flow | report ↗ |
| 2021-FY | $296M | $179M | $292M+ $15M short-term inv. | —$10M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-01 | HARRISON THOMAS L · director | Award / grant | 4,443 | $6.89 | $31K | Form 4 |
| 2026-10-01 | Wright Timothy · director | Award / grant (derivative) | 1,178.764 | — | — | Form 4 |
| 2026-08-10 | ARMEN GARO H · director, See Remarks | Award / grant (derivative) | 1,971,500 | — | — | Form 4 |
| 2026-08-05 | Marcucci Marco Tullio · director | Award / grant (derivative) | 7,500 | — | — | Form 4 |
| 2026-08-05 | Corvese Brian · director | Award / grant (derivative) | 100,000 | — | — | Form 4 |
| 2026-08-05 | HARRISON THOMAS L · director | Award / grant (derivative) | 50,000 | — | — | Form 4 |
| 2026-08-05 | Buell Jennifer · director, See Remarks | Award / grant (derivative) | 200,000 | — | — | Form 4 |
| 2026-08-05 | Hirsch Susan B · director | Award / grant (derivative) | 50,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 87 reporting institutions held 9.2M shares ($30.0M, 20.4% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 1,440,232 | $4.8M |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1,195,109 | $4.0M |
| 3 | Siren, L.L.C. | 1,064,250 | $3.6M |
| 4 | MARSHALL WACE, LLP | 688,203 | $2.3M |
| 5 | BlackRock, Inc. | 545,662 | $1.8M |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 348,395 | $1.2M |
| 7 | MORGAN STANLEY | 295,821 | $988K |
| 8 | RENAISSANCE TECHNOLOGIES LLC | 285,646 | $954K |
| 9 | Man Group plc | 278,980 | $932K |
| 10 | RAYMOND JAMES FINANCIAL INC | 239,554 | $800K |
| 11 | UBS Group AG | 234,439 | $783K |
| 12 | VANGUARD FIDUCIARY TRUST CO | 200,498 | $670K |
| 13 | Connor, Clark & Lunn Investment Management Ltd. | 198,502 | $663K |
| 14 | TWO SIGMA INVESTMENTS, LP | 170,922 | $571K |
| 15 | PANAGORA ASSET MANAGEMENT INC | 163,148 | $545K |